Soleus Private Equity Fund III, L.P. 13D and 13G filings for Aprea Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-01 5:00 pm Purchase | 2026-04-01 | 13G | APREA THERAPEUTICS INC APRE | Soleus Private Equity Fund III, L.P. | 1,271,080 9.990% | 1,271,080 (New Position) | Filing |